Mylan CEO Heather Bresch said Friday that the local generic drug company is still shooting for the end of July or early August for a special meeting at which it will ask its shareholders to approve the proposed acquisition of Perrigo.
“The goal is to get a shareholder vote as soon as we can,” Ms. Bresch said at an investor conference in New York City hosted by Sanford Bernstein.
If it receives the nod from Mylan shareholders, the company plans to take its proposal to Perrigo shareholders.
Although Perrigo’s board has rejected the offer as too low, Ms. Bresch said she believes it will win approval from Perrigo stockholders.
“We think it’s a very fair and compelling offer,” she said. “We believe Perrigo shareholders are very happy with the offer on the table.”
Ms. Bresch said Mylan’s board was open to discussions with Perrigo, which specializes in store brand over-the-counter medications.
Read More
“I still believe that could happen. If that happens, could there be different things put on the table? Absolutely,” she said when asked if Mylan might revise its bid.
At the same time, Mylan is hoping to fend off an unsolicited takeover offer from Israel’s Teva Pharmaceutical Industries.
Mylan management has derided Teva, the biggest generic drug company in the world, as a poorly run company on a downhill slide.
“We just don’t think Teva is the right company” to combine with, Ms. Bresch said. “They are getting ready to go off the cliff.”
Still, she said, “down the road” joining with Teva might make sense, but only if Mylan’s management team were in charge.
Teva recently purchased a 1.35 percent stake in Mylan by buying shares in the open market.
“I have no idea what Teva is thinking,” Ms. Bresch said when asked what Teva might do next.
Patricia Sabatini: psabatini@post-gazette.com.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.